VERTEX PHARMACEUTICALS INC / MA Proceeds from Sale of Debt Securities, Available-for-sale
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Proceeds from Sale of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for the quarter ending 2019-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for the quarter ending 2019-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for the quarter ending 2018-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for the quarter ending 2018-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for fiscal 2019 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for fiscal 2018 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for fiscal 2017 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA proceeds from sale of debt securities, available-for-sale for fiscal 2016 was $0.00.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2019-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-08-01 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2017-09-30 | $0.00 10-Q · filed 2018-10-25 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |